The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
about
We must not let protestors derail trials of pre-exposure prophylaxis for HIVThe development of vaginal microbicides for the prevention of HIV transmissionLabKey Server: an open source platform for scientific data integration, analysis and collaborationThe spread, treatment, and prevention of HIV-1: evolution of a global pandemicDeveloping an HIV vaccine: the role of efficacy studies in nonhuman primatesA shot in the arm for AIDS vaccine researchExpanding access to HIV preventionThe future of HIV vaccine research and the role of the Global HIV Vaccine EnterpriseOrganizing the HIV vaccine development effortLabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assaysAIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccinesPhylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.Improving defences at the portal of HIV entry: mucosal and innate immunity.Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.HIV prevention cost-effectiveness: a systematic review.Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells.International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.Critical issues in mucosal immunity for HIV-1 vaccine development.Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.Quest for the AIDS vaccineDevelopment and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cellsOpinion: do we have the architecture for health aid right? Increasing global aid effectiveness.An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases.Transcriptional profiling of experimental CD8(+) lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239A new era in HIV vaccine development.Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.Antibody-based HIV-1 vaccines: recent developments and future directions.
P2860
Q21092391-D86637B5-FF13-4D3E-B2F4-A223CA560D44Q21092393-9B023F9A-0563-4B66-9647-86B163FA0066Q21284332-F1BFAD2C-ACB1-4ACF-A5D7-7A8DB573A931Q22241890-7CECB478-7DA0-4D21-8F55-3288778961CAQ24792383-B48F1418-4C52-4021-8CBD-D542039F4480Q24801040-F34FEBDA-52E1-43BC-8DB5-57655A93B109Q25257866-C2664338-9FDC-4F7F-AF26-4063F2F741C0Q27010375-1AA93F83-3A9F-42F5-A114-163960EF6101Q27026502-7D43E1A0-7FF6-4064-8036-53D65AD1097CQ28743608-1732DF35-E475-416B-B197-0962F3159CC1Q30394227-E7B72150-72D1-4FBF-9381-3EC7477A3883Q30404569-FBC7E823-580C-4E95-9E00-68359D162B13Q30494738-58F4247C-B8D8-4CE7-9168-AEAA680BF8F6Q30620607-CA266B3F-8533-4B12-9FE0-FC53CDBE5DF1Q30892555-CC597CE2-65A6-4A23-BCEC-6313BECA4AF6Q33578049-1521C44D-BC9C-4E3F-9EBA-8FACFA0276ECQ33618007-03001F21-2E46-473D-B2B3-707C7F5304B2Q34150070-F8C752C3-F791-4187-B855-760B402E6E85Q34357068-D170F439-2DB4-4D9A-A52D-A3F48007893BQ34459985-CD3C1BD3-C85B-4096-9A83-458CDD1159FEQ34848486-DB0E0808-3E5B-4D75-B53E-B9107C4D7F5CQ35140032-8032E1E5-D42F-43AF-AE19-E2160A59108CQ35868653-8C28DF8B-C333-4A34-BC5A-ABB782D29534Q35903806-0E6E2EB6-EC49-4D14-80B6-AFA04A7EDC8FQ36262994-C2EBABC9-4C4F-4DE3-A343-5C4641B5573EQ36445532-6C200692-EF92-48D6-9BAD-763C11D05A9DQ36506883-EF67A2D7-C511-4BCD-927D-4C4C4D6D84C6Q36777835-7EE5E0DA-6A86-4AD4-BE97-3E8CB42D4E67Q36827168-FD0089AA-B0BB-4710-ADBE-AAAA00022371Q42738983-9786FD06-10E8-4DF1-82DD-DC2560C69683
P2860
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@ast
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@en
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@en-gb
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@nl
type
label
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@ast
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@en
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@en-gb
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@nl
altLabel
The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan
@en
prefLabel
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@ast
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@en
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@en-gb
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@nl
P2860
P1433
P1476
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan
@en
P2860
P356
10.1371/JOURNAL.PMED.0020025
P407
P50
P577
2005-02-01T00:00:00Z